US biotechnology firm Pfenex is looking to raise more than US$45 million to further its biosimilars pipeline.
Pfenex looking for funding for its biosimilars pipeline
Home/Pharma News
|
Posted 27/06/2014
0
Post your comment

Pfenex filed a registration statement with the US Securities and Exchange Commission for a proposed initial public offering of its common stock on 6 June 2014.
Pfenex is focussed on biosimilars, and its lead product is PF582, a biosimilar of Roche’s Lucentis (ranibizumab). The monoclonal antibody drug is indicated for the treatment of patients with wet age-related macular degeneration (AMD), macular oedema following retinal vein occlusion (RVO) and diabetic macular oedema (DME); all conditions of the eye causing vision loss.
The company’s biosimilars pipeline also includes six biosimilars that are being developed as part of a joint venture with Strides Arcolab subsidiary Aguila Biotech [1]. These include biosimilars of multiple sclerosis treatment Betaseron (interferon beta-1b) (PF530), chronic hepatitis B/C treatment Pegasys (peg-interferon alpha-2a) (PF694), peg-interferon beta (PF756), neutropenia treatment Neulasta (peg-filgrastim) (PF529), human growth hormone (PF444) and leukaemia treatment Oncaspar (peg-aspargase) (PF690). Pfenex is also developing a biosimilar of arthritis drug Cimzia (certolizumab-pegol) (PF688) on its own.
Pfenex intends to use approximately US$40 million of the funds raised from the sale of shares in the company to fund clinical development of PF582, including approximately US$5 million for the ongoing phase Ib/IIa trial and approximately US$35 million for the planned phase III trial. The company expects to start the phase III trial of PF582 in mid-2015, with data expected in 2017. The patent on Lucentis only expires in 2019, giving Pfenex some time yet to work on its biosimilar.
Pfenex will also use approximately US$5 million to fund Pfenex’s share of the planned phase III clinical development of PF530, which it expects to start in the second half of 2014.
Any remaining cash will be used to fund the research and development of other products, including PF694, for which it expects to start a phase I trial in the second half of 2015.
Related article
Biosimilars developments during 2013
Reference
1. GaBI Online - Generics and Biosimilars Initiative. Agila Biotech and Pfenex make biosimilars dealIndia [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 27]. Available from: www.gabionline.net/Biosimilars/News/Agila-Biotech-and-Pfenex-make-biosimilars-deal
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.
Source: Pfenex, SEC
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment